46 research outputs found
Spaceborne Photonics Institute
This report describes in chronological detail the development of the Spaceborne Photonics Institute as a sustained research effort at Hampton University in the area of optical physics. This provided the research expertise to initiate a PhD program in Physics. Research was carried out in the areas of: (1) modelling of spaceborne solid state laser systems; (2) amplified spontaneous emission in solar pumped iodine lasers; (3) closely simulated AM0 CW solar pumped iodine laser and repeatedly short pulsed iodine laser oscillator; (4) a materials spectroscopy and growth program; and (5) laser induced fluorescence and atomic and molecular spectroscopy
Service quality assessment of a referral hospital in Southern Iran with SERVQUAL technique: patients’ perspective
Hepatite Cholestatique Induite par I'Administration Prolongee de I'Acide Nalidixique (Rapport d'un cas)
Cholestatic hepatitis induced by prolonged administration of nalidixic acid: Anti biotics like other drugs may generally produce hepatic benign lesions. We have recently observed a case of cholestatic hepatitis by prolonged administration of nalidixic acid. This hepatitis have regressed rapidly after discont inuin-c the dru g. This case dose not excluded the value of nalidixic acid asa strong antibiotic but it to the category of hepat otoxic drugs
Terrestrial solar-pumped iodine gas laser with minimum threshold concentration requirements
Comparison Training of Shogi Evaluation Functions with Self-Generated Training Positions and Moves
Coping with endogeneity and unobserved heterogeneity in real-time clustering critical crash occurrences nested within weather and road surface conditions
The impact of sofosbuvir/daclatasvir or ribavirin in patients with severe COVID-19
OBJECTIVES: Sofosbuvir and daclatasvir are direct-acting antivirals highly effective against hepatitis C virus. There is some in silico and in vitro evidence that suggests these agents may also be effective against SARS-CoV-2. This trial evaluated the effectiveness of sofosbuvir in combination with daclatasvir in treating patients with COVID-19. METHODS: Patients with a positive nasopharyngeal swab for SARS-CoV-2 on RT-PCR or bilateral multi-lobar ground-glass opacity on their chest CT and signs of severe COVID-19 were included. Subjects were divided into two arms with one arm receiving ribavirin and the other receiving sofosbuvir/daclatasvir. All participants also received the recommended national standard treatment which, at that time, was lopinavir/ritonavir and single-dose hydroxychloroquine. The primary endpoint was time from starting the medication until discharge from hospital with secondary endpoints of duration of ICU stay and mortality. RESULTS: Sixty-two subjects met the inclusion criteria, with 35 enrolled in the sofosbuvir/daclatasvir arm and 27 in the ribavirin arm. The median duration of stay was 5 days for the sofosbuvir/daclatasvir group and 9 days for the ribavirin group. The mortality in the sofosbuvir/daclatasvir group was 2/35 (6%) and 9/27 (33%) for the ribavirin group. The relative risk of death for patients treated with sofosbuvir/daclatasvir was 0.17 (95% CI 0.04-0.73, P = 0.02) and the number needed to treat for benefit was 3.6 (95% CI 2.1-12.1, P < 0.01). CONCLUSIONS: Given these encouraging initial results, and the current lack of treatments proven to decrease mortality in COVID-19, further investigation in larger-scale trials seems warranted